Complications of intravenous gammaglobulin in neuromuscular and other diseases

Muscle and Nerve

Volumn 19, Issue 3, 1996, Pages 388-391

  Bertorini, Tulio E ^a,b,c   Nance, Adriana M ^a   Horner, Linda H ^a   Greene, William ^b   Gelfand, Michael S ^b   Jaster, J Howard ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Methodist Hospitals of Memphis   (United States)

^c Memphis Health Center   (United States)

Author keywords

complications; gammaglobulin; neuromuscular diseases

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN G;

ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNITY; BRAIN INFARCTION; DOSE RESPONSE; FEVER; FLUID RETENTION; HEADACHE; HEART FAILURE; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALAISE; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; RASH; RESTLESSNESS; VOMITING;

AUTOIMMUNE DISEASES; FEMALE; HEADACHE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; NAUSEA; NEUROMUSCULAR DISEASES; RETROSPECTIVE STUDIES; VOMITING;

EID: 0030069541     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199603)19:3<388::AID-MUS20>3.0.CO;2-N     Document Type: Article

References (30)

1. ASHP: Therapeutic guidelines for intravenous immunoglobulin. Clin Pharmacol 1992;II:111-116.
2. Berkman SA, Lee ML, Gale RP: Clinical uses of intravenous immunoglobulins. Ann Intern Med 1990;112:278-292.
3. Björkander J, Cunningham-Rundles C, Lundin P, Olsson R, Soderstrom R, Hanson LA: Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-111.
4. Björkander J, Wadsworth C, Hanson LA: 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection 1985;13:102-110.
5. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
6. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin (IVIG) therapy in neurologic patients. Neurology 1995;45:A236.
7. Casteels-Van Daele M, Wijndaele L, Hanninck K, Gillis P: Intravenous immune globulin and acute aseptic meningitis. N Engl J Med 1990;323:614-615.
8. Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-226.
9. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
10. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
11. Leong GM, Thayer Z, Antony G, Golagiuri S, Dwyer J, Kidson W, Fisher R, Wakefield D: High-dose intravenous immunoglobulin therapy for insulin-dependent diabetes melitus, in Imbach P (ed): Immunotherapy with Intravenous Immunoglobulins. McLean, VA, Academic Press, 1991, pp 269-282.
12. Lever AML, Webster ADB, Brown D, Thomas HL: Non-A, non-B hepatitis after intravenous gammaglobulin [letter]. Lancet 1985;i:587.
13. Lockner D, Bratt G, Lindborg A, Tornebohm E: Acute unidentified hepatitis in a hypogammaglobulinemic patient on intravenous gammaglobulin successfully treated with interferon. Acta Med Scand 1987;221:413-415.
14. Matsumoto S, Kobayashi N, Gohya N: Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. Eur J Pediatr 1981;136:167-171
15. NIH Consensus Conference: Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264: 3189-3193.
16. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdon HS, Wedgwood RJ: Non-A, non-B hepatitis and intravenous immunoglobulin [letter]. Lancet 1985;i:404-405.
17. Pawlotsky JM, Bouvier M, Deforges L, Duval J, Bierling P, Dhumeaux D: Chronic hepatitis C after high-dose intravenous immunoglobulin [letter]. Transfusion 1994;34:86-87.
18. Rault R, Piraino B, Johnston JR, Oral A: Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991;36:83-86.
19. Schiano TD, Bellary SV, Black M: Possible transmission of hepatitis C virus infection with intravenous immunoglobulin. Ann Intern Med 1995;122:802.
20. Schiff RI: Transmission of viral infections through intravenous immune globulin [editorial]. N Engl J Med 1994; 331:1649-1650.
21. Scribner CL, Kapit RM, Phillips ET, Rickles NM: Aseptic meningitis and intravenous immunoglobulin therapy. Ann Intern Med 1994;121:305-306.
22. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121: 259-262.
23. Silben PL, Knezevic WV, Bridge DT: Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-258.
24. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
25. Thornton CA, Ballow M: Safety of intravenous immunoglobulin [editorial]. Arch Neurol 1993;50:135-136.
26. Thornton CA, Griggs RC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease. Ann Neurol 1994;35:260-268.
27. U.S. Department of Health and Human Services: Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. Morbidity and Mortality Weekly Report 1994;43:505-508.
28. van der Meché FGA, Schmitz PIM: The Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
29. van Doorn PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
30. Williams PE, Yap PL, Gillon J, Crawford RJ, Galea G, Cuthbertson B: Non-A, non-B hepatitis transmission by intravenous immunoglobulin [letter]. Lancet 1988;ii:501.